MCM-2 Levels as a Potential Biomarker for Predicting High-Risk Breast Cancer Patients According to TAILORx Classification

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• International Agency for Research on Cancer GLOBOCAN. 2020 population fact sheets 3 2021 international agency for research on cancer. GLOBOCAN; 2021. Available from: https://gco.iarc.fr/today/data/factsheets/populations/792-turkey-fact-sheets.pdf. Accessed August 24, 2023.
   Google Scholar
• Özmen V, Özmen T, Doğru V. Breast cancer in Turkey; an analysis of 20.000 patients with breast cancer. Eur J Breast Health. 2019;15(3):141. PMID: 31312788 PMCID: PMC6619786. doi:10.5152/ejbh.2019.4890
   PubMed Web of Science ®Google Scholar
• Howlader N, Altekruse SF, Li CI, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5):dju055. doi:10.1093/jnci/dju055
   PubMedGoogle Scholar
• Neves H, Kwok HF. In sickness and in health: the many roles of the minichromosome maintenance proteins. Biochim Biophys Acta Rev Cancer. 2017;1868(1):295–308. doi:10.1016/j.bbcan.2017.06.001
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen H, Zhang J, et al. MCM family in gastrointestinal cancer and other malignancies: from functional characterization to clinical implication. Biochim Biophys Acta. 2020;2020:1874.
   Google Scholar
• Maiorano D, Lutzmann M, Mechali M. MCM proteins and DNA replication. Curr Opin Cell Biol. 2006;18:130–136. doi:10.1016/j.ceb.2006.02.006
   PubMed Web of Science ®Google Scholar
• Pruitt SC, Bailey KJ, Freeland A. Reduced Mcm2 expression results in severe stem/progenitor cell deficiency and cancer. Stem Cells. 2007;25:3121–3132. doi:10.1634/stemcells.2007-0483
   PubMed Web of Science ®Google Scholar
• Wu W, Wang X, Shan C, Li Y, Li F. Minichromosome maintenance protein 2 correlates with the malignant status and regulates proliferation and cell cycle in lung squamous cell carcinoma. Onco Targets Ther. 2018;11:5025–5034. doi:10.2147/OTT.S169002
   PubMed Web of Science ®Google Scholar
• Obermann Ellen C, Went P, Zimpfer A, et al. Expression of minichromosome maintenance protein 2 as a marker for proliferation and prognosis in diffuse large B-cell lymphoma: a tissue microarray and clinico-pathological analysis. BMC Cancer. 2005;5(1):1–8. doi:10.1186/1471-2407-5-1
   PubMedGoogle Scholar
• Ramnath N, Hernandez FJ, Tan DF, et al. MCM2 is an independent predictor of survival in patients with nonsmall- cell lung cancer. J Clin Oncol. 2001;19:4259–4266. doi:10.1200/JCO.2001.19.22.4259
   PubMed Web of Science ®Google Scholar
• Issac MSM, Yousef E, Tahir MR, Gaboury LA. MCM2, MCM4, and MCM6 in breast cancer: clinical utility in diagnosis and prognosis. Neoplasia. 2019;21:1015–1035. doi:10.1016/j.neo.2019.07.011
   PubMed Web of Science ®Google Scholar
• Gonzalez MA, Pinder SE, Callagy G, et al. Minichromosome maintenance protein 2 is a strong independent prognostic marker in breast cancer. J Clin Oncol. 2003;21:4306–4313. doi:10.1200/JCO.2003.04.121
   PubMed Web of Science ®Google Scholar
• Chen R, Hu B, Jiang M, et al. Bioinformatic analysis of the expression and clinical significance of the DNA replication regulator MCM complex in bladder cancer. Int J Gen Med. 2022;Volume 15:5465–5485. doi:10.2147/IJGM.S368573
   Web of Science ®Google Scholar
• Zhou J, Wang M, Zhou Z, et al. Expression and prognostic value of MCM family genes in osteosarcoma. Front Mol Biosci. 2021;8:668402. doi:10.3389/fmolb.2021.668402
   PubMed Web of Science ®Google Scholar
• Lin CY, Wu HY, Hsu YL, et al. Suppression of drug-resistant non-small-cell lung cancer with inhibitors targeting minichromosomal maintenance protein. J Med Chem. 2020;63:3172–3187. doi:10.1021/acs.jmedchem.9b01783
   PubMed Web of Science ®Google Scholar
• Harris LN, Ismaila N, McShane LM, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2016;34(10):1134–1150. doi:10.1200/jco.2015.65.2289
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Anderson BO, Balassanian R, et al. Breast cancer, version 1 2016. J Natl Compr Canc Netw. 2015;13(12):1475–1485. doi:10.6004/jnccn.2015.0176
   PubMed Web of Science ®Google Scholar
• Henry NL, Somerfield MR, Abramson VG, et al. Role of patient and disease factors in adjuvant systemic therapy decision making for early-stage, operable breast cancer: American society of clinical oncology endorsement of cancer care Ontario guideline recommendations. J Clin Oncol. 2016;34(19):2303–2311. doi:10.1200/jco.2015.65.8609
   PubMed Web of Science ®Google Scholar
• Sparano Joseph A, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111–121. doi:10.1056/NEJMoa1804710
   PubMed Web of Science ®Google Scholar
• Updated TAILORx results confirm women with intermediate recurrence score can skip chemotherapy. Available from: https://www.breastcancer.org/research-news/updated-tailorx-results-confirm-women-with-intermediate-recurrence-score-can-skip-chemotherapy. Accessed August 24, 2023.
   Google Scholar
• Özmen V, Çakar B, Gökmen E, et al. Cost effectiveness of gene expression profiling in patients with early-stage breast cancer in a middle-income country, Turkey: results of a prospective multicenter study. Eur J Breast Health. 2019;15(3):183.
   PubMed Web of Science ®Google Scholar
• Ozmen V, Atasoy A, Gokmen E, et al. Correlations between Oncotype DX Recurrence Score and classic risk factors in early breast cancer: results of a prospective multicenter study in Turkey. J Breast Health. 2016;12:107–111. doi:10.5152/tjbh.2016.2874
   PubMedGoogle Scholar
• Ozmen V, Atasoy A, Gokmen E, et al. Impact of Oncotype DX Recurrence Score on treatment decisions: results of a prospective multicenter study in Turkey. Cureus. 2016;8(3):30.
   Google Scholar
• Panousis D, Ntasiou P, Grosomanidis D, et al. Impact of Oncotype DX on chemotherapy assignment: a retrospective single-center study on female breast cancer patients. therapy. 2017;15:20.
   Google Scholar
• Thakur SS, Li H, Chan AMY, et al. The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer. PLoS One. 2018;13(1):e0188983. doi:10.1371/journal.pone.0188983
   PubMed Web of Science ®Google Scholar
• Crager M, Wijayawardana SR, Gruver AM, et al. Population-based estimate for the correlation of the Oncotype DX Breast Recurrence Score® result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2−, node-positive early breast cancer. Breast Cancer Res. 2022;24:1–7. doi:10.1186/s13058-022-01571-7
   PubMed Web of Science ®Google Scholar
• Pilanci KN, Unal C, Ordu C, et al. Correlation between clinicopathologic factors and recurrence score according to TAILOR x risk category in patients with hormone receptor positive early-stage breast cancer. J BU ON. 2021;2021:1.
   Google Scholar
• Piccart M, Van’t Veer LJ, Poncet C, et al. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the Phase 3 randomised MINDACT trial with an exploratory analysis by age. Lancet Oncol. 2021;22(4):476–488. doi:10.1016/S1470-2045(21)00007-3
   PubMed Web of Science ®Google Scholar
• Andre F, Ismaila N, Allison KH, et al. Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update. J Clin Oncol. 2022;40:1816–1837. doi:10.1200/JCO.22.00069
   PubMed Web of Science ®Google Scholar
• NCCN. NCCN clinical Practice guidelines in oncology V.2. Breast Cancer; 2023. Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed February 7, 2023.].
   Google Scholar
• Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24:3726–3734. doi:10.1200/JCO.2005.04.7985
   PubMed Web of Science ®Google Scholar
• Gluz O, Nitz UA, Christgen M, et al. West German study group phase III planb trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment. J Clin Oncol. 2016;34:2341–2349. doi:10.1200/JCO.2015.63.5383
   PubMed Web of Science ®Google Scholar
• Tang G, Shak S, Paik S, et al. Comparison of the prognostic and predictive utilities of the 21-gene recurrence score assay and adjuvant! For women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20. Breast Cancer Res Treat. 2011;127:133–142. doi:10.1007/s10549-010-1331-z
   PubMed Web of Science ®Google Scholar
• Lopez F, Belloc F, Lacombe F, et al. Modalities of synthesis of Ki67 antigen during the stimulation of lymphocytes. Cytometry. 1991;12:42–49. doi:10.1002/cyto.990120107
   PubMedGoogle Scholar
• Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133:1710–1715. doi:10.4049/jimmunol.133.4.1710
   PubMed Web of Science ®Google Scholar
• Van Dierendonck JH, Keijzer R, van de Velde CJ, et al. Nuclear distribution of the Ki-67 antigen during the cell cycle: comparison with growth fraction in human breast cancer cells. Cancer Res. 1989;49:2999–3006.
   PubMed Web of Science ®Google Scholar
• Clark BZ, Dabbs DJ, Cooper KL, Bhargava R, Thakur SS, Li H. Impact of progesterone receptor semiquantitative immunohistochemical result on Oncotype DX recurrence score: a quality assurance study of 1074 cases. Appl Immunohistochem Mol Morphol. 2013;21(4):287–291. doi:10.1097/PAI.0b013e31826f80c9
   PubMedGoogle Scholar
• Park S, Han Y, Liu Y, et al. Adjuvant chemotherapy and survival among patients 70 years of age and younger with node-negative breast cancer and the 21-gene recurrence score of 26–30. Breast Cancer Res. 2019;21(1):1–11. doi:10.1186/s13058-019-1190-4
   PubMed Web of Science ®Google Scholar
• Mosley JD, Keri RA. Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists. BMC Med Genomics. 2008;1:11. doi:10.1186/1755-8794-1-11
   PubMed Web of Science ®Google Scholar
• Heidebrecht HJ, Buck F, Haas K, et al. Monoclonal antibodies Ki-S3 and Ki-S5 yield new data on the ‘Ki-67’ proteins. Cell Prolif. 1996;29:413–425. doi:10.1111/j.1365-2184.1996.tb00984.x
   PubMed Web of Science ®Google Scholar
• Laskey R. The Croonian Lecture 2001 hunting the antisocial cancer cell: MCM proteins and their exploitation. Philos Trans R Soc Lond B Biol Sci. 2005;360:1119–1132. doi:10.1098/rstb.2005.1656
   PubMed Web of Science ®Google Scholar
• Joshi S, Watkins J, Gazinska P, et al. Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value. BMC Cancer. 2015;15:1–12. doi:10.1186/s12885-015-1531-3
   PubMed Web of Science ®Google Scholar
• Wojnar A, Kobierzycki C, Krolicka A, et al. Correlation of Ki-67 and MCM-2 proliferative marker expression with grade of histological malignancy (G) in ductal breast cancers. Folia Histochem Cytobiol. 2010;48(3):442–446. doi:10.2478/v10042-010-0069-0
   PubMed Web of Science ®Google Scholar
• Shetty A, Loddo M, Fanshawe T, et al. DNA replication licensing and cell cycle kinetics of normal and neoplastic breast. Br J Cancer. 2005;93:1295–1300. doi:10.1038/sj.bjc.6602829
   PubMed Web of Science ®Google Scholar
• Tőkés T, Tőkés A-M, Szentmártoni G, et al. Prognostic and clinicopathological correlations of cell cycle marker expressions before and after the primary systemic therapy of breast cancer. Pathol Oncol Res. 2020;26:1499–1510. doi:10.1007/s12253-019-00726-w
   PubMed Web of Science ®Google Scholar
• Yousef EM, Furrer D, Laperriere DL, et al. MCM2: an alternative to Ki-67 for measuring breast cancer cell proliferation. Mod Pathol. 2017;30(5):682–697. doi:10.1038/modpathol.2016.231
   PubMed Web of Science ®Google Scholar
• Sakai H, Kimura H, Otsubo K, et al. Minichromosome maintenance 2 is an independent predictor of survival in patients with lung adenocarcinoma. Mol Clin Oncol. 2022;14:1–7.
   Google Scholar
• Samad A, Haque F, Nain Z, et al. Computational assessment of MCM2 transcriptional expression and identification of the prognostic biomarker for human breast cancer. Heliyon. 2020;6(10):e05087. doi:10.1016/j.heliyon.2020.e05087
   PubMed Web of Science ®Google Scholar
• Loddo M, Kingsbury SR, Rashid M, et al. Cell-cycle-phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer. Br J Cancer. 2009;100:959–970. doi:10.1038/sj.bjc.6604924
   PubMed Web of Science ®Google Scholar
• Ünal Ç, Tunçer G, Çopur B, et al. Clinical and inflammation marker features of cancer patients with COVID-19: data of Istanbul, Turkey multicenter cancer patients (2020–2022). Curr Med Res Opin. 2023;39(7):987–996. doi:10.1080/03007995.2023.2223917
   PubMed Web of Science ®Google Scholar
• Kalelioglu T, Karamustafalioglu N, Emul M, et al. Detecting biomarkers associated with antipsychotic-induced extrapyramidal syndromes by using machine learning techniques. J Psychiatr Res. 2023;158:300–304. doi:10.1016/j.jpsychires.2023.01.003
   PubMed Web of Science ®Google Scholar